

## Quick Guide

# Bcl10

Margot Thome and  
Jürg Tschopp

**What is it?** Bcl10 is an intracellular signalling protein which positively regulates lymphocyte proliferation by connecting antigen receptor-induced signals of B and T cells to the activation of the transcription factor NF- $\kappa$ B.

**It first came to prominence...** as a candidate gene near the chromosomal translocation t(1;14)(p22;q32) found in B-cell lymphomas of the mucosa associated lymphoid tissue (MALT). At the same time, Bcl10 was found by database searches for novel proteins with a caspase recruitment domain (CARD). Bcl stands for B cell lymphoma or leukemia, and is used for genes found through chromosomal translocations associated with these diseases. Some other Bcl proteins include the cell cycle regulatory protein Bcl1/Cyclin D1 and the anti-apoptotic protein Bcl2.

**Previously ascribed function...** A pro-apoptotic function was given to Bcl10 based on overexpression studies and on the characterization of genetic mutations predicting the expression of truncated, potentially




Figure 1. Bcl10 and its relatives Bcl10, viral E10 and the three CARD-containing MAGUKs (CARMA1, 2 and 3/Bimp3, 2 and 1/CARD11, 14 and 10) contain an amino-terminal CARD motif. The viral protein has a carboxy-terminal consensus site (CysCys) for lipid modification through a geranylgeranyl moiety. The CARMA/Bimp homologues contain other protein-protein interaction domains (coiled coil, PDZ, SH3 and GUK).




Figure 2. Working model for Bcl10. Bcl10 is a positive regulator of antigen-receptor induced NF- $\kappa$ B activation. Members of the TRAF (TNF receptor associated factor) family of scaffolding proteins may relay Bcl10 to the NF- $\kappa$ B signalling machinery. An interaction of Bcl10 with PKC $\theta$  is suggested from the similar phenotypes of the PKC $\theta$  and Bcl10 knock-out mice — lack of NF- $\kappa$ B-dependent T-cell activation.

non-functional forms of Bcl10 in lymphomas and other tumors.

**Can we live without it?** Probably not, about one third of Bcl10 deficient mice embryos develop lethal exencephaly. Surviving mice are severely immunodeficient, and their B and T lymphocytes are defective in antigen receptor-induced cellular activation and proliferation.

**Any related proteins?** Several. Its closest homologue is the equine herpesvirus-2 protein E10, which has an amino-terminal CARD motif of about 50% sequence identity with Bcl10. Three CARD-containing proteins of the membrane-associated guanylate kinase (MAGUK) family, designated CARMA (CARD-MAGUK) or Bimp (Bcl10-interacting MAGUK protein) also have considerable CARD sequence identity with Bcl10.

**How does Bcl10 work?** It's not clear, but the molecular mechanism probably involves binding of Bcl10's amino-terminal portion to the CARMA proteins via a CARD-CARD interaction, and binding of its carboxy-terminal portion to MLT1, a caspase-like molecule identified from another recurrent chromosomal translocation of MALT lymphomas.

**How does its herpesviral homologue work?** vE10 is targeted to the plasma membrane via a covalent lipid modification where it induces phosphorylation and membrane recruitment of Bcl10, leading to the constitutive activation of the transcription factor NF- $\kappa$ B.

**Is Bcl10 mutated in tumors?** Translocation of Bcl10 to the immunoglobulin heavy chain locus in the MALT-associated chromosomal translocation t(1;14)(p22;q32) predicts its deregulated expression because of the proximity of potent B cell transcriptional enhancers or the generation of mutant forms of Bcl10 due to the action of the immunoglobulin somatic hypermutation mechanism. Mutated forms of Bcl10 encoding carboxy-terminal truncations have been found, but whether they are expressed in MALT is an ongoing debate. The phenotype of the Bcl10-deficient mice suggests that upregulation of Bcl10 or expression of an active form of Bcl10 might mimic a constitutive NF- $\kappa$ B signal from the antigen receptor and promote antigen independent growth and lymphoma progression.

### Where can I find out more?

- Ruland, J., Duncan, G.S. *et al.* (2001). Bcl10 is a positive regulator of antigen receptor-induced activation of NF- $\kappa$ B and neural tube closure. *Cell* 104, 33-42.
- Willis, T.G., Jadayel, D.M., Du, M.Q. *et al.* (1999). Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. *Cell* 96, 35-45.
- Gaide, O., Martinon, M. *et al.* (2001). Carma1, a CARD-containing binding partner of Bcl10, induces Bcl10 phosphorylation and NF- $\kappa$ B activation. *FEBS Lett.* 496, 121-127.
- Uren, A.G., O'Rourke, K. *et al.* (2000). Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. *Mol. Cell.* 6, 961-967.

University of Lausanne, Institute of Biochemistry, 155 chemin des Boveresses, CH-1066 Epalinges, Switzerland.